PDS Biotechnology Accepted for Oral Presentation at the 34th Annual Society for Immunotherapy of Cancer Annual Meeting
06 nov. 2019 16h05 HE
|
PDS Biotechnology Corporation
PRINCETON, N.J., Nov. 06, 2019 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immuno-oncology company developing multiple therapies based on the company’s...
PDS Biotechnology Completes Manufacturing of Clinical Batches of PDS0101
22 oct. 2019 08h30 HE
|
PDS Biotechnology Corporation
PRINCETON, N.J., Oct. 22, 2019 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immuno-oncology company pioneering development of multi-functional novel...
PDS Biotechnology Corp. Announces Clinical Collaboration with Merck
03 oct. 2019 08h30 HE
|
PDS Biotechnology Corporation
BERKELEY HEIGHTS, N.J., Oct. 03, 2019 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (“PDS Biotechnology”) (Nasdaq: PDSB), a clinical-stage immuno-oncology company pioneering the development of...
PDS Biotechnology Prioritizes Development of PDS0101 in Advanced Cancers Following Promising Phase 1 Clinical Outcome Data
01 oct. 2019 08h30 HE
|
PDS Biotechnology Corporation
BERKELEY HEIGHTS, N.J., Oct. 01, 2019 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (“PDS Biotechnology”) (Nasdaq: PDSB), a clinical-stage immuno-oncology company pioneering the development of...
PDS Biotechnology Reports Clinical Data for Its Novel Immunotherapy PDS0101 in Follow up to Phase 1 Human Trial
19 sept. 2019 08h00 HE
|
PDS Biotechnology Corporation
60% of evaluable patients demonstrated a clinical response Clinical activity observed at all dose levels Data support previously reported in-vivo induction of active...
PDS Biotechnology to Present at the 21st Annual H.C. Wainwright Global Investment Conference
03 sept. 2019 08h30 HE
|
PDS Biotechnology Corporation
BERKELEY HEIGHTS, N.J., Sept. 03, 2019 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (“PDS Biotechnology”) (Nasdaq: PDSB), a clinical-stage immuno-oncology company pioneering the development of...
PDS Biotechnology Reports Second Quarter 2019 Financial Results And Provides Business Update
01 août 2019 06h00 HE
|
PDS Biotechnology Corporation
BERKELEY HEIGHTS, N.J., Aug. 01, 2019 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (“PDS Biotechnology”) (Nasdaq: PDSB), a clinical-stage immuno-oncology company pioneering the development of...
PDS Biotechnology Corporation Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
03 juil. 2019 08h30 HE
|
PDS Biotechnology Corporation
BERKELEY HEIGHTS, N.J., July 03, 2019 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (“PDS Biotechnology”) (Nasdaq: PDSB), a clinical-stage immuno-oncology company pioneering the development of...
PDS Biotechnology Corporation Granted U.S. and European Patents for Versamune® - GM-CSF Combination to Overcome Tumor Immune Suppression
19 juin 2019 08h30 HE
|
PDS Biotechnology Corporation
BERKELEY HEIGHTS, N.J., June 19, 2019 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (“PDS Biotechnology”) (Nasdaq: PDSB), a clinical-stage immuno-oncology company pioneering the development of...
PDS Biotechnology Signs Cooperative Research and Development Agreement with National Cancer Institute to Perform a Phase 2 Clinical Study of PDS0101 in Combination with Other Immune-modulating Agents in Advanced HPV-related Cancers
29 mai 2019 08h30 HE
|
PDS Biotechnology Corporation
BERKELEY HEIGHTS, N.J., May 29, 2019 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (“PDS Biotechnology”) (Nasdaq: PDSB), a clinical-stage immuno-oncology company pioneering the development of...